

Brief Contents

SECTION 1

General Principles of Pharmacology, 1

- 1 Basic Principles of Pharmacology, 3
- 2 Pharmacokinetics I: Drug Administration, Absorption, and Distribution, 15
- 3 Pharmacokinetics II: Drug Elimination, 31
- 4 Drug Receptors, 43

SECTION 2

Pharmacology of the Central Nervous System, 57

- 5 General Principles of Central Nervous System Pharmacology, 59
- 6 Sedative-Hypnotic and Antianxiety Drugs, 69
- 7 Drugs to Treat Affective Disorders: Depression and Bipolar Syndrome, 83
- 8 Antipsychotic Drugs, 101
- 9 Antiepileptic Drugs, 115

- 10 Pharmacological Management of Parkinson Disease, 131

- 11 General Anesthetics, 149

- 12 Local Anesthetics, 165

SECTION 3

Drugs Affecting Skeletal Muscle, 177

- 13 Skeletal Muscle Relaxants, 179

SECTION 4

Drugs Used to Treat Pain and Inflammation, 199

- 14 Opioid Analgesics, 201

- 15 Nonsteroidal Anti-Inflammatory Drugs, 219

- 16 Pharmacological Management of Rheumatoid Arthritis and Osteoarthritis, 237

- 17 Patient-Controlled Analgesia, 261

SECTION 5

Autonomic and Cardiovascular Pharmacology, 277

- 18 Introduction to Autonomic Pharmacology, 279
- 19 Cholinergic Drugs, 289
- 20 Adrenergic Drugs, 301
- 21 Antihypertensive Drugs, 315
- 22 Treatment of Angina Pectoris, 335
- 23 Treatment of Cardiac Arrhythmias, 349
- 24 Treatment of Congestive Heart Failure, 359
- 25 Treatment of Coagulation Disorders and Hyperlipidemia, 375

SECTION 6

Respiratory and Gastrointestinal Pharmacology, 397

- 26 Respiratory Drugs, 399
- 27 Gastrointestinal Drugs, 421

SECTION 7

Endocrine Pharmacology, 433

- 28 Introduction to Endocrine Pharmacology, 435
- 29 Adrenocorticosteroids, 447

- 30 Male and Female Hormones, 465
- 31 Thyroid and Parathyroid Drugs: Agents Affecting Bone Mineralization, 491
- 32 Pancreatic Hormones and the Treatment of Diabetes Mellitus, 507

SECTION 8

Chemotherapy of Infectious and Neoplastic Diseases, 529

- 33 Treatment of Infections I: Antibacterial Drugs, 531
- 34 Treatment of Infections II: Antiviral Drugs, 557
- 35 Treatment of Infections III: Antifungal and Antiparasitic Drugs, 581
- 36 Cancer Chemotherapy, 599
- 37 Immunomodulating Agents, 625
- 38 Complementary and Alternative Medications, 641

Appendix A Drugs Administered by Iontophoresis and Phonophoresis, 657

Appendix B Drugs of Abuse, 659

Appendix C Answers to Case Study Questions, 661

Glossary, 673

Index, 681

Contents



SECTION 1

General Principles of Pharmacology, 1

CHAPTER 1. Basic Principles of Pharmacology, 3

Relevance of Pharmacology in Rehabilitation, 3

Drug Nomenclature, 4

Substitution of Generic Drugs for Brand-Name Products, 5

What Constitutes a Drug: Development and Approval of Therapeutic Agents, 6

Drug Approval Process, 6

Orphan Drugs, 7

Off-Label Prescribing, 8

Prescription Versus Over-the-Counter Medication, 8

Controlled Substances, 9

Basic Concepts in Drug Therapy, 9

Dose-Response Curves and Maximal Efficacy, 9

Potency, 10

Elements of Drug Safety, 11

Quantal Dose-Response Curves and the Median Effective Dose, 11

Median Toxic Dose, 11

Therapeutic Index, 12

Summary, 12

References, 12

CHAPTER 2. Pharmacokinetics I: Drug Administration, Absorption, and Distribution, 15

Routes of Administration, 15

Enteral, 15

Parenteral, 17

Transdermal, 18

Bioavailability and Drug Absorption Across the Cell Membrane, 19

Membrane Structure and Function, 19

Movement Across Membrane Barriers, 20

Distribution of Drugs Within the Body, 23

Factors Affecting Distribution, 23

Volume of Distribution, 24

Drug Storage, 24

Storage Sites, 24

Adverse Consequences of Drug Storage, 25

Newer Techniques for Drug Delivery, 25

Controlled-Release Preparations, 25

Implanted Drug Delivery Systems, 25

Targeting Drug Delivery to Specific Cells and Tissues, 26

Summary, 26

References, 27

CHAPTER 3. Pharmacokinetics II: Drug Elimination, 31

Biotransformation, 31

Cellular Mechanisms of Drug Biotransformation, 31

Organs Responsible for Drug Biotransformation, 33

Enzyme Induction, 33

Drug Excretion, 33

Drug Elimination Rates, 34

Clearance, 34

Half-Life, 35

Dosing Schedules and Plasma Concentration, 35

Variations in Drug Response and Metabolism, 36

Genetics, 36

Disease, 37

Drug Interactions, 37

Age, 38

Diet, 38

Sex, 38
Other Factors, 39
Summary, 39
References, 39

CHAPTER 4. Drug Receptors, 43

Receptors Located on the Cell's Surface, 43
Surface Receptors Linked Directly to Ion Channels, 43
Surface Receptors Linked Directly to Enzymes, 44
Surface Receptors Linked to Regulatory (G) Proteins and the Role of the Second Messenger, 44
Intracellular Receptors, 46
Drug-Receptor Interactions, 46
Functional Aspects of Drug-Receptor Interactions, 47
Drug Selectivity and Receptor Subtypes, 47
Dose-Response, 48
Classification of Drugs: Agonist Versus Antagonist, 49
Competitive Versus Noncompetitive Antagonists, 49
Partial Agonists, 50
Mixed Agonist-Antagonists and Inverse Agonists, 50
Receptor Regulation, 51
Receptor Desensitization and Down-Regulation, 51
Receptor Supersensitivity, 52
Nonreceptor Drug Mechanisms, 52
Summary, 52
References, 53



SECTION 2

Pharmacology of the Central Nervous System, 57

CHAPTER 5. General Principles of Central Nervous System Pharmacology, 59

CNS Organization, 59
Cerebrum, 59
Basal Ganglia, 59
Diencephalon, 60
Mesencephalon and Brainstem, 60
Cerebellum, 60
Limbic System, 61
Spinal Cord, 61
The Blood-Brain Barrier, 61
CNS Neurotransmitters, 62
Acetylcholine, 63
Monoamines, 63
Amino Acids, 63
Peptides, 63
Other Transmitters, 64
The General Mechanisms of CNS Drugs, 64

Summary, 66
References, 66

CHAPTER 6. Sedative-Hypnotic and Antianxiety Drugs, 69

Sedative-Hypnotic Drugs, 69
Benzodiazepines, 69
Nonbenzodiazepines, 72
Pharmacokinetics, 73
Problems and Adverse Effects of Sedative-Hypnotics, 73
Antianxiety Drugs, 75
Benzodiazepines, 75
Buspirone, 76
Use of Antidepressants in Anxiety, 76
Other Antianxiety Drugs, 77
Problems and Adverse Effects of Anxiolytics, 78
Special Concerns for Rehabilitation Patients, 78
Case Study, 79
Sedative-Hypnotic Drugs, 79
Summary, 80
References, 80

CHAPTER 7. Drugs to Treat Affective Disorders: Depression and Bipolar Syndrome, 83

Depression, 83
Pathophysiology of Depression, 84
Antidepressant Drugs, 86
Pharmacokinetics of Antidepressants, 90
Problems and Adverse Effects, 90
Antidepressants and Chronic Pain, 92
Bipolar Disorder, 93
Lithium, 94
Other Drugs for Bipolar Disorder, 95
Special Concerns for Rehabilitation Patients, 95
Case Study, 97
Antidepressant Drugs, 97
Summary, 97
References, 97

CHAPTER 8. Antipsychotic Drugs, 101

Schizophrenia, 101
Pathogenesis of Schizophrenia, 102
Neurotransmitter Changes in Schizophrenia, 102
Antipsychotics Mechanism of Action, 103
Antipsychotic Drugs, 105
Traditional Antipsychotics, 105
Atypical Antipsychotics, 105
Pharmacokinetics, 106
Other Uses of Antipsychotics, 106
Problems and Adverse Effects, 107
Extrapyramidal Symptoms, 107

Nonmotor Effects, 109

Other Side Effects, 110

Special Concerns for Rehabilitation Patients, 110

Case Study, 111

Antipsychotic Drugs, 111

Summary, 111

References, 111

CHAPTER 9. Antiepileptic Drugs, 115

Classification of Epileptic Seizures, 116

Rationale for Drug Treatment, 117

Antiseizure Drugs, 118

First-Generation Antiseizure Drugs, 118

Second-Generation Agents, 121

Selection of a Specific Antiepileptic Agent, 124

Pharmacokinetics, 125

Special Precautions During Pregnancy, 125

Treatment of Status Epilepticus, 126

Withdrawal of Antiseizure Medications, 126

Special Concerns for Rehabilitation Patients, 127

Case Study, 127

Antiepileptic Drugs, 127

Summary, 128

References, 128

**CHAPTER 10. Pharmacological Management of
Parkinson Disease, 131**

Pathophysiology of Parkinson Disease, 132

**Etiology of Parkinson Disease: Genetic and Environmental
Factors, 133**

Genetic Factors, 133

Environmental Factors, 134

Therapeutic Agents in Parkinsonism, 134

Levodopa, 135

Pharmacokinetics of Levodopa, 135

Use of Peripheral Decarboxylase Inhibitors, 136

Problems and Adverse Effects of Levodopa Therapy, 137

Drug Holidays From Levodopa, 139

Other Drugs to Treat Parkinson Disease, 140

Dopamine Agonists, 140

Anticholinergic Drugs, 141

Amantadine, 141

Monoamine Oxidase B Inhibitors, 141

Catechol-O-Methyltransferase Inhibitors, 142

**Clinical Course of Parkinson Disease: When to Use Specific
Drugs, 142**

Neurosurgical Interventions in Parkinson Disease, 143

Special Concerns For Rehabilitation Patients, 144

Case Study, 144

Anti-Parkinson Drugs, 144

Summary, 145

References, 145

CHAPTER 11. General Anesthetics, 149

Requirements for General Anesthesia, 149

Induction Stages of General Anesthesia, 150

**General Anesthetic Agents: Classification and Use
According to Route of Administration, 150**

Inhalation Anesthetics, 150

Intravenous Anesthetics, 153

Pharmacokinetics, 154

Mechanisms of Action, 154

Adjuvants in General Anesthesia, 156

Preoperative Medications, 156

Neuromuscular Blockers, 157

Nondepolarizing Blockers, 159

Depolarizing Blocker, 159

Special Concerns for Rehabilitation Patients, 160

Case Study, 160

General Anesthetics, 160

Summary, 161

References, 161

CHAPTER 12. Local Anesthetics, 165

Types of Local Anesthetics, 165

Pharmacokinetics, 167

Clinical Use of Local Anesthetics, 167

Topical Administration, 167

Transdermal Administration, 167

Infiltration Anesthesia, 168

Peripheral Nerve Block, 168

Central Neural Blockade, 168

Sympathetic Blockade, 169

Intravenous Regional Anesthesia (Bier Block), 170

Mechanism of Action, 170

Differential Nerve Block, 171

Systemic Effects of Local Anesthetics, 172

Special Concerns for Rehabilitation Patients, 173

Case Study, 174

Local Anesthetics, 174

Summary, 174

References, 174



SECTION 3

Drugs Affecting Skeletal Muscle, 177

CHAPTER 13. Skeletal Muscle Relaxants, 179

**Increased Muscle Tone: Spasticity Versus Muscle
Spasms, 179**

Antispasm Drugs, 180

Diazepam, 180

Centrally Acting Antispasm Drugs, 181

Antispasticity Drugs, 183

- Baclofen, 183*
- Intrathecal Baclofen, 184*
- Dantrolene Sodium, 185*
- Diazepam, 186*
- Gabapentin, 186*
- Tizanidine, 187*

Use of Botulinum Toxin as a Muscle Relaxant, 187

- Mechanism of Action, 188*
- Clinical Use of Botulinum Toxin, 189*
- Limitations and Adverse Effects, 190*

Pharmacokinetics, 191

Special Concerns for Rehabilitation Patients, 191

Case Study, 193

- Muscle Relaxants, 193*

Summary, 193

References, 194



SECTION 4

Drugs Used to Treat Pain and Inflammation, 199

CHAPTER 14. Opioid Analgesics, 201

Sources of Opioid Analgesics, 201

Endogenous Opioid Peptides and Opioid Receptors, 202

- Endogenous Opioids, 202*
- Opioid Receptors, 202*

Classification of Specific Agents, 203

- Strong Agonists, 203*
- Mild-to-Moderate Agonists, 205*
- Mixed Agonist-Antagonists, 206*
- Antagonists, 206*

Pharmacokinetics, 206

Mechanism of Action, 207

- Sites of Opioid Effects, 207*
- Effects of Opioids on Synaptic Activity, 209*

Clinical Applications, 210

- Treatment of Pain, 210*
- Use of Opioids in Patient-Controlled Analgesia, 211*
- Other Opioid Uses, 211*

Problems and Adverse Effects, 211

Concepts of Addiction, Tolerance, and Physical Dependence, 211

- Tolerance, 212*
- Physical Dependence, 212*
- Tolerance and Dependence During Therapeutic Opioid Use, 213*
- Opioid-Induced Hyperalgesia, 213*
- Pharmacological Treatment of Opioid Addiction, 214*

Special Concerns for Rehabilitation Patients, 214

Case Study, 215

- Opioid Analgesics, 215*

Summary, 216

References, 216

CHAPTER 15. Nonsteroidal Anti-Inflammatory Drugs, 219

Aspirin and Other NSAIDs: General Aspects, 219

Prostaglandins, Thromboxanes, and Leukotrienes, 220

- Eicosanoid Biosynthesis, 220*
- Role of Eicosanoids in Health and Disease, 220*

Mechanism of NSAID Action: Inhibition of Prostaglandin and Thromboxane Synthesis, 222

Aspirin: The Prototypical NSAID, 223

Clinical Applications of Aspirinlike Drugs, 224

- Treatment of Pain and Inflammation, 224*
- Treatment of Fever, 224*
- Treatment of Vascular Disorders, 224*
- Prevention of Cancer, 224*

Problems and Adverse Effects of Aspirinlike Drugs, 224

- Gastrointestinal Problems, 224*
- Cardiovascular Problems, 225*
- Other Side Effects, 226*

Comparison of Aspirin With Other NSAIDs, 227

COX-2 Selective Drugs, 229

- COX-2 Drugs and the Risk of Heart Attack and Stroke, 230*

Acetaminophen, 230

Pharmacokinetics of NSAIDs and Acetaminophen, 232

Special Concerns for Rehabilitation Patients, 232

Case Study, 233

- Nonsteroidal Anti-Inflammatory Drugs, 233*

Summary, 233

References, 233

CHAPTER 16. Pharmacological Management of Rheumatoid Arthritis and Osteoarthritis, 237

Rheumatoid Arthritis, 237

- Immune Basis for Rheumatoid Arthritis, 239*
- Overview of Drug Therapy in Rheumatoid Arthritis, 239*
- NSAIDs, 240*
- Glucocorticoids, 241*
- Disease-Modifying Antirheumatic Drugs, 242*
- Traditional (Nonbiological) DMARDs, 243*
- Biological DMARDs, 247*
- Other DMARDs, 249*
- DMARD Combinations Used in Rheumatoid Arthritis, 249*
- Dietary Implications for Rheumatoid Arthritis, 250*

Osteoarthritis, 250

- Acetaminophen and NSAIDs, 251*
- Viscosupplementation, 251*
- Glucosamine and Chondroitin Sulfate, 252*

Special Concerns for Rehabilitation Patients, 253

Case Study, 253
Rheumatoid Arthritis, 253
Summary, 254
References, 254

CHAPTER 17. Patient-Controlled Analgesia, 261

Pharmacokinetic Basis for PCA, 261
PCA Dosing Strategies and Parameters, 262
Types of Analgesics Used for PCA, 263
PCA Pumps, 264
Administration Routes During PCA, 265
IV PCA, 265
Epidural PCA, 266
Regional PCA, 267
Transdermal PCA, 267
Other Potential Administration Routes for PCA, 268
Comparison of PCA to Other Methods of Analgesic Administration, 268
Comparison of PCA to Continuous Nerve Blocks, 269
Problems and Adverse Effects of PCA, 270
Pharmacological Adverse Effects, 270
Problems With PCA Delivery, 270
Special Concerns for Rehabilitation Patients, 271
Case Study, 272
Patient-Controlled Analgesia, 272
Summary, 272
References, 272



SECTION 5

Autonomic and Cardiovascular Pharmacology, 277

CHAPTER 18. Introduction to Autonomic Pharmacology, 279

Anatomy of the Autonomic Nervous System: Sympathetic and Parasympathetic Divisions, 279
Preganglionic and Postganglionic Neurons, 280
Sympathetic Organization, 280
Parasympathetic Organization, 280
Functional Aspects of the Sympathetic and Parasympathetic Divisions, 280
Function of the Adrenal Medulla, 282
Autonomic Integration and Control, 282
Autonomic Neurotransmitters, 283
Acetylcholine and Norepinephrine, 283
Other Autonomic Neurotransmitters, 283
Autonomic Receptors, 284
Cholinergic Receptors, 284
Adrenergic Receptors, 286

Pharmacological Significance of Autonomic Receptors, 287
Summary, 288
References, 288

CHAPTER 19. Cholinergic Drugs, 289

Cholinergic Receptors, 289
Cholinergic Stimulants, 290
Direct-Acting Cholinergic Stimulants, 290
Indirect-Acting Cholinergic Stimulants, 291
Clinical Applications of Cholinergic Stimulants, 292
Problems and Adverse Effects of Cholinergic Stimulants, 293
Anticholinergic Drugs, 293
Source and Mechanism of Action of Antimuscarinic Anticholinergic Drugs, 294
Clinical Applications of Antimuscarinic Drugs, 294
Problems and Adverse Effects of Anticholinergic Drugs, 297
Summary, 297
References, 298

CHAPTER 20. Adrenergic Drugs, 301

Adrenergic Receptor Subclassifications, 302
Adrenergic Agonists, 303
Alpha-1-Selective Agonists, 303
Alpha-2-Selective Agonists, 304
Beta-1-Selective Agonists, 305
Beta-2-Selective Agonists, 305
Drugs With Mixed Alpha- and Beta-Agonist Activity, 306
Adrenergic Antagonists, 307
Alpha Antagonists, 307
Beta Antagonists, 309
Other Drugs That Inhibit Adrenergic Neurons, 312
Summary, 313
References, 313

CHAPTER 21. Antihypertensive Drugs, 315

Normal Control of Blood Pressure, 316
Pathogenesis of Hypertension, 316
Essential Versus Secondary Hypertension, 316
Possible Mechanisms in Essential Hypertension, 317
Drug Therapy, 318
Diuretics, 318
Sympatholytic Drugs, 320
Vasodilators, 323
Renin-Angiotensin System Inhibitors, 324
Calcium Channel Blockers, 326
Drug Selection for Specific Patients With Hypertension, 327
Nonpharmacological Treatment of Hypertension, 328
Special Concerns for Rehabilitation Patients, 329
Case Study, 329
Hypertension, 329

Summary, 330
References, 330

CHAPTER 22. Treatment of Angina Pectoris, 335

Drugs Used to Treat Angina Pectoris, 335

- Organic Nitrates, 335*
- Beta-Adrenergic Blockers, 338*
- Calcium Channel Blockers, 339*

Other Drugs Affecting Myocardial Oxygen Balance in Angina Pectoris, 340

Use of Anticoagulants in Angina Pectoris, 341

Treatment of Specific Types of Angina Pectoris, 341

- Stable Angina, 341*
- Variant Angina (Prinzmetal Ischemia), 343*
- Unstable Angina, 343*

Nonpharmacologic Management of Angina Pectoris, 344

Special Concerns for Rehabilitation Patients, 344

Case Study, 345

- Antianginal Drugs, 345*

Summary, 346

References, 346

CHAPTER 23. Treatment of Cardiac Arrhythmias, 349

Cardiac Electrophysiology, 349

- Cardiac Action Potentials, 349*
- Normal Cardiac Rhythm, 350*
- Normal Conduction of the Cardiac Action Potential, 351*

Mechanisms of Cardiac Arrhythmias, 351

Types of Arrhythmias, 352

Classification of Antiarrhythmic Drugs, 352

- Class I: Sodium Channel Blockers, 352*
- Class II: Beta Blockers, 354*
- Class III: Drugs That Prolong Repolarization, 354*
- Class IV: Calcium Channel Blockers, 355*

Other Drugs Used to Treat Arrhythmias, 355

Nonpharmacological Treatment of Arrhythmias, 355

Special Concerns for Rehabilitation Patients, 356

Case Study, 356

- Antiarrhythmic Drugs, 356*

Summary, 357

References, 357

CHAPTER 24. Treatment of Congestive Heart Failure, 359

Pathophysiology of Congestive Heart Failure, 360

- The Vicious Cycle of Heart Failure, 360*
- Congestion in Left and Right Heart Failure, 361*

Pharmacotherapy, 362

Drugs That Increase Myocardial Contraction Force (Positive Inotropic Agents), 362

- Digitalis, 362*
- Phosphodiesterase Inhibitors, 365*
- Dopamine and Dobutamine, 366*

Agents That Decrease Cardiac Workload, 367

- Drugs Affecting the Renin-Angiotensin System, 367*
- Adverse Effects of Drugs Affecting the Renin-Angiotensin System, 368*
- Beta Blockers, 368*
- Diuretics, 369*
- Vasodilators, 370*

Special Concerns for Rehabilitation Patients, 371

Case Study, 371

- Congestive Heart Failure, 371*

Summary, 372

References, 372

CHAPTER 25. Treatment of Coagulation Disorders and Hyperlipidemia, 375

Normal Mechanism of Blood Coagulation, 376

- Clot Formation, 376*
- Clot Breakdown, 377*

Drugs Used to Treat Overactive Clotting, 377

- Anticoagulants, 377*
- Antiplatelet Drugs, 381*
- Fibrinolytics, 383*

Treatment of Clotting Deficiencies, 385

- Hemophilia, 385*
- Deficiencies of Vitamin K-Dependent Clotting Factors, 386*
- Antifibrinolytics, 386*

Agents Used to Treat Hyperlipidemia, 387

- HMG-CoA Reductase Inhibitors (Statins), 387*
- Fibric Acids, 388*
- Other Lipid-Lowering Agents, 389*
- Adverse Effects of Antihyperlipidemic Agents, 389*

Special Concerns for Rehabilitation Patients, 390

Case Study, 391

- Clotting Disorders, 391*

Summary, 391

References, 392



SECTION 6

Respiratory and Gastrointestinal Pharmacology, 397

CHAPTER 26. Respiratory Drugs, 399

Drugs Used to Treat Respiratory Tract Irritation and Control Respiratory Secretions, 399

- Antitussives, 399*
- Decongestants, 400*
- Antihistamines, 401*
- Mucolytics and Expectorants, 402*

Drugs Used to Maintain Airway Patency in Obstructive Pulmonary Disease, 403

- Beta-Adrenergic Agonists, 403*
- Xanthine Derivatives, 406*

Anticholinergic Drugs, 407

Glucocorticoids, 408

Cromones, 409

Leukotriene Inhibitors, 409

Treatment of Bronchial Asthma, 410

Pathophysiology of Bronchial Asthma, 410

Long-Term Management of Asthma, 410

Treatment of Reversible Bronchospasm in COPD, 412

Treatment of Respiratory Problems in Cystic Fibrosis, 412

Special Concerns for Rehabilitation Patients, 413

Case Study, 414

Respiratory Drugs, 414

Summary, 415

References, 415

CHAPTER 27. Gastrointestinal Drugs, 421

Drugs Used to Control Gastric Acidity and Secretion, 421

Antacids, 422

H₂ Receptor Blockers, 423

Proton Pump Inhibitors, 423

Treatment of Helicobacter Pylori Infection in Gastric Ulcer Disease, 425

Other Agents Used to Control and Treat Gastric Ulcers, 425

Antidiarrheal Agents, 426

Opioid Derivatives, 426

Bismuth Salicylate, 427

Miscellaneous Agents Used to Treat Diarrhea, 427

Laxatives and Cathartics, 428

Specific Agents and Mechanism of Action, 428

Adverse Effects, 429

Miscellaneous Gastrointestinal Drugs, 429

Digestants, 429

Emetics, 429

Antiemetics, 429

Cholelitholytic Agents, 430

Special Concerns for Rehabilitation Patients, 430

Case Study, 430

Gastrointestinal Drugs, 430

Summary, 431

References, 431



SECTION 7

Endocrine Pharmacology, 433

CHAPTER 28. Introduction to Endocrine Pharmacology, 435

Primary Endocrine Glands and Their Hormones, 435

Hypothalamus and Pituitary Gland, 436

Thyroid Gland, 437

Parathyroid Gland, 438

Pancreas, 438

Adrenal Gland, 438

Gonads, 439

Endocrine Physiology and Pharmacology, 439

Hormone Chemistry, 439

Synthesis and Release of Hormones, 440

Feedback Control Mechanisms in Endocrine Function, 440

Hormone Transport, 441

Hormone Effects on the Target Cell, 441

Clinical Use of Endocrine Drugs, 443

Replacement Therapy, 443

Diagnosis of Endocrine Disorders, 443

Treatment of Excessive Endocrine Function, 443

Exploitation of Beneficial Hormone Effects, 444

Use of Hormones to Alter Normal Endocrine Function, 444

Use of Hormones in Nonendocrine Disease, 444

Summary, 444

References, 444

CHAPTER 29. Adrenocorticosteroids, 447

Steroid Synthesis, 447

Glucocorticoids, 449

Role of Glucocorticoids in Normal Function, 449

Mechanism of Action of Glucocorticoids, 450

Physiological Effects of Glucocorticoids, 450

Clinical Uses of Glucocorticoids, 453

Glucocorticoid Use in Endocrine Disorders, 454

Glucocorticoid Use in Nonendocrine Conditions, 454

Adverse Effects of Glucocorticoids, 455

Adrenocortical Suppression, 456

Drug-Induced Cushing Syndrome, 456

Breakdown of Supporting Tissues, 456

Other Adverse Effects, 457

Drugs That Inhibit Adrenocortical Hormone

Biosynthesis, 457

Mineralocorticoids, 457

Regulation of Mineralocorticoid Secretion, 458

Mechanism of Action and Physiological Effects of Mineralocorticoids, 458

Therapeutic Use of Mineralocorticoid Drugs, 459

Adverse Effects of Mineralocorticoid Agonists, 459

Mineralocorticoid Antagonists, 460

Special Concerns for Rehabilitation Patients, 460

Case Study, 461

Adrenocorticosteroids, 461

Summary, 462

References, 462

CHAPTER 30. Male and Female Hormones, 465

Androgens, 465

Source and Regulation of Androgen Synthesis, 465

Physiological Effects of Androgens, 467

Clinical Use of Androgens, 467

Replacement Therapy, 467

Catabolic States, 467

Delayed Puberty, 468

Breast Cancer, 468
Anemia, 468
Hereditary Angioedema, 468
Specific Agents, 468
Adverse Effects of Clinical Androgen Use, 469
Antiandrogens, 469

Androgen Abuse, 470
Effects of Androgens on Athletic Performance, 471
Adverse Effects of Androgen Abuse, 472

Estrogen and Progesterone, 472
Effects of Estrogen and Progesterone on Sexual Maturation, 473
Regulation and Effects of Hormonal Synthesis During the Menstrual Cycle, 473
Female Hormones in Pregnancy and Parturition, 475

Pharmacological Use of Estrogen and Progesterone, 475
Conditions Treated With Estrogen and Progesterone, 475
Use of Hormone Replacement Therapy Following Menopause, 476
Specific Agents, 477
Adverse Effects of Estrogen and Progesterone, 477

Other Drugs That Affect Estrogen and Progesterone Activity, 478
Selective Estrogen Receptor Modulators, 478
Antiestrogens, 479
Antiprogestins, 479

Hormonal Contraceptives, 480
Types of Contraceptive Preparations, 480
Mechanism of Contraceptive Action, 482
Adverse Effects of Hormonal Contraceptives, 482

Case Study, 483
Male and Female Hormones, 483

Special Concer ns for Rehabilitation P atients, 484
Summary, 484
References, 485

CHAPTER 31. Thyroid and Parathyroid Drugs:
Agents Affecting Bone Mineralization, **491**

Hormones of the Thyroid Gland, 491
Synthesis of Thyroid Hormones, 491
Regulation of Thyroid Hormone Release, 493
Physiological Effects of Thyroid Hormones, 493
Mechanism of Action of Thyroid Hormones, 493

Treatment of Thyroid Disorders, 494
Hyperthyroidism, 494
Hypothyroidism, 496

Parathyroid Hormone, 497

Regulation of Bone Mineral Homeostasis, 498
Parathyroid Hormone and Bone Formation, 498
Vitamin D, 498
Calcitonin, 498
Other Hormones, 499

Pharmacological Control of Bone Mineral Homeostasis, 499
Calcium Supplements, 501
Vitamin D, 501
Bisphosphonates, 501
Calcitonin, 502
Estrogen Therapy, 503
Other Agents That Promote Bone Mineral Content, 503

Special Concer ns for Rehabilitation P atients, 504
Case Study, 504
Agents Affecting Bone Mineral Metabolism, 504

Summary, 505
References, 505

CHAPTER 32. Pancreatic Hor mones and the Treatment of Diabetes Mellitus, 507

Structure and Function of the Endocrine P ancreas, 507
Insulin, 508
Effects of Insulin on Carbohydrate Metabolism, 508
Effects of Insulin on Protein and Lipid Metabolism, 508
Cellular Mechanism of Insulin Action, 508

Glucagon, 509
Control of Insulin and Glucagon Release, 510
Diabetes Mellitus, 510
Type 1 Diabetes, 511
Type 2 Diabetes, 511
Effects and Complications of Diabetes Mellitus, 512

Use of Insulin in Diabetes Mellitus, 513
Therapeutic Effects and Rationale for Use, 513
Insulin Preparations, 513
Administration of Insulin, 515
Intensive Insulin Therapy, 516
Adverse Effects of Insulin Therapy, 516

Primary Agents in T ype 2 Diabetes, 517
Drugs That Stimulate Insulin Secretion and Supply, 517
Insulin Sensitizers, 519
Other Antidiabetics, 520

Prevention of T ype 1 Diabetes Mellitus: The P otential Role of Immune-Based Therapies, 520

Nonpharmacological Inter vention in Diabetes Mellitus, 521
Dietary Management and Weight Reduction, 521
Exercise, 521
Tissue Transplants and Gene Therapy, 521

Special Concer ns for Rehabilitation P atients, 522
Case Study, 523
Diabetes Mellitus, 523

Summary, 523
References, 523



SECTION 8

Chemotherapy of Infectious and Neoplastic Diseases, 529

CHAPTER 33. Treatment of Infections I: Antibacterial Drugs, 531

Bacteria: Basic Concepts, 532

Bacterial Structure and Function, 532

Pathogenic Effects of Bacteria, 532

Bacterial Nomenclature and Classification, 532

Spectrum and Activity of Antibacterial Drugs, 533

Spectrum of Antibacterial Activity, 533

Bactericidal Versus Bacteriostatic Activity, 533

Basic Mechanisms of Antibacterial Drugs, 533

Inhibition of Bacterial Cell Wall Synthesis and Function, 534

Inhibition of Bacterial Protein Synthesis, 534

Inhibition of Bacterial DNA/RNA Synthesis and Function, 535

Specific Antibacterial Agents, 535

Antibacterial Drugs That Inhibit Bacterial Cell Wall Synthesis and Function, 535

Penicillins, 536

Cephalosporins, 537

Carbapenems, 538

Other Agents That Inhibit Bacterial Cell Wall Synthesis, 538

Use of Beta-Lactamase Inhibitors, 539

Drugs That Inhibit Bacterial Protein Synthesis, 539

Aminoglycosides, 539

Erythromycin and Other Macrolides, 540

Other Agents That Inhibit Bacterial Protein Synthesis, 541

Drugs That Inhibit Bacterial DNA/RNA Synthesis and Function, 543

Aminosalicylic Acid, 543

Clofazimine, 543

Dapsone, 543

Fluoroquinolones, 543

Metronidazole, 544

Mupirocin, 544

Rifamycins, 544

Sulfonamides, 545

Trimethoprim, 545

Other Antibacterial Drugs, 545

Capreomycin, 545

Daptomycin, 546

Isoniazid, 546

Methenamine, 546

Nitrofurantoin, 546

Pyrazinamide, 546

Clinical Use of Antibacterial Drugs: Relationship to Specific Bacterial Infections, 546

Resistance to Antibacterial Drugs, 549

Special Concerns for Rehabilitation Patients, 551

Case Study, 551

Antibacterial Drugs, 551

Summary, 552

References, 552

CHAPTER 34. Treatment of Infections II: Antiviral Drugs, 557

Viral Structure and Function, 557

Classification of Viruses, 557

Characteristics of Viruses, 558

Viral Replication, 559

Specific Antiviral Drugs, 560

Acyclovir and Valacyclovir, 561

Amantadine and Rimantadine, 561

Cidofovir, 562

Docosanol, 563

Dolutegravir, Elvitegravir, and Raltegravir, 563

Enfuvirtide and Maraviroc, 563

Famciclovir and Penciclovir, 564

Foscarnet, 564

Ganciclovir and Valganciclovir, 564

Imiquimod, 565

Trifluridine, 565

Oseltamivir and Zanamivir, 565

Protease Inhibitors, 565

Reverse Transcriptase Inhibitors, 566

Ribavirin, 567

Viral Resistance, 568

Interferons, 568

Synthesis and Cellular Effects of Interferons, 568

Pharmacological Applications of Interferons, 569

Adverse Effects of Interferons, 570

Control of Viral Infection With Vaccines, 570

HIV and the Treatment of AIDS, 571

Inhibition of HIV Proliferation in Infected Individuals, 571

Anti-HIV Drug Combinations: Use of Highly Active Antiretroviral Therapy, 573

HIV Vaccines, 574

Management of Opportunistic Infections, 574

Special Concerns for Rehabilitation Patients, 576

Case Study, 576

Antiviral Drugs, 576

Summary, 577

References, 577

CHAPTER 35. Treatment of Infections III: Antifungal and Antiparasitic Drugs, 581

Antifungal Agents, 581

- Systemic Antifungal Agents, 584
- Topical Antifungal Agents, 586

Antiprotozoal Agents, 587

- Antimalarial Agents, 588
- Drugs Used to Treat Protozoal Infections in the Intestines and Other Tissues, 591
- Other Antiprotozoal Drugs, 593

Anthelmintics, 593

- Albendazole, 593
- Diethylcarbamazine, 594
- Ivermectin, 594
- Mebendazole, 594
- Praziquantel, 594
- Pyrantel Pamoate, 595
- Thiabendazole, 595
- Other Anthelmintics, 595

Special Concerns for Rehabilitation Patients, 595

Case Study, 596

- Antifungal Drugs, 596

Summary, 596

References, 596

CHAPTER 36. Cancer Chemotherapy, 599

General Principles, 600

- Cytotoxic Strategy, 600
- Cell-Cycle–Specific Versus Cell-Cycle–Nonspecific Drugs, 600
- Concepts of Growth Fraction and Cell Kill, 600
- Prevalence and Management of Adverse Effects, 601

Specific Anticancer Drugs, 602

- Alkylating Agents, 602
- Antimetabolites, 603
- Anticancer Antibiotics, 605
- Antimicrotubule Agents, 605
- Topoisomerase Inhibitors, 608
- Anticancer Hormones, 608
- Targeted and Biological Therapies, 610
- Platinum Coordination Complexes, 613
- Aspirin and Other NSAIDs, 613
- Miscellaneous Agents, 614

Combination Chemotherapy, 616

Use of Anticancer Drugs With Other Treatments, 617

Success of Anticancer Drugs, 617

Resistance to Anticancer Drugs, 618

Future Perspectives, 618

Special Concerns for Rehabilitation Patients, 619

Case Study, 620

- Cancer Chemotherapy, 620

Summary, 621

References, 621

CHAPTER 37. Immunomodulating Agents, 625

Overview of the Immune Response, 626

Pharmacological Suppression of the Immune Response, 627

Specific Immunosuppressive Agents, 627

- Azathioprine, 627
- Cyclophosphamide, 629
- Cyclosporine, 629
- Glucocorticoids, 629
- Methotrexate, 630
- Mycophenolate Mofetil, 630
- Sulfasalazine, 631
- Sirolimus and Other mTOR Inhibitors, 631
- Tacrolimus, 631
- Other Methods of Immunosuppression, 632

Immunostimulants, 634

- Bacille Calmette-Guérin, 634
- Immune Globulin, 634

Other Immunomodulators, 635

Special Concerns for Rehabilitation Patients, 635

Case Study, 636

- Immunomodulating Agents, 636

Summary, 637

References, 637

CHAPTER 38. Complementary and Alternative Medications, 641

Problems Associated With CAMs, 641

- Misconceptions About CAM Safety, 641
- Failure to Report CAM Use, 642
- Lack of Standards for Quality and Purity of CAMs, 642
- Delayed Use of Conventional Medications, 642

Potential Adverse Effects of CAMs, 643

Specific CAMs, 643

- Bee Venom, 643
- Echinacea, 644
- Garlic, 644
- Ginger, 645
- Ginkgo Biloba, 645
- Ginseng, 645
- Glucosamine and Chondroitin, 645
- Kava, 646

Melatonin, 646
Saw Palmetto, 646
St. John's Wort, 647
Valerian, 647

Vitamins and Minerals, 647

Vitamins, 647
Minerals, 649

Special Concerns for Rehabilitation Patients, 650

Case Study, 651

Complementary and Alternative Medications, 651

Summary, 652

References, 652

**APPENDIX A: Drugs Administered by
Iontophoresis and
Phonophoresis, 657**

APPENDIX B: Drugs of Abuse, 659

**APPENDIX C: Answers to Case Study
Questions, 661**

Glossary, 673

Index, 681